دورية أكاديمية
أعرض في EDS

Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study.

التفاصيل البيبلوغرافية
العنوان: Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study.
المؤلفون: Alcaraz A; Urology Department, Hospital Clínic, Universitat de Barcelona, IDIBAPS, 08036 Barcelona, Spain., Rodríguez-Antolín A; Urology Department, Research Group in Men's Integral Health, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain., Carballido-Rodríguez J; Urology Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Majadahonda, Spain., Castro-Díaz D; Urology Department, Hospital Universitario de Canarias, 38320 Tenerife, Spain., Esteban-Fuertes M; Urology Department, Hospital Nacional de Parapléjicos, 45004 Toledo, Spain., Cózar-Olmo JM; Urology Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain., Ficarra V; Urology Department, University of Messina, 98125 Messina, Italy., Medina-López R; Urology Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain., Fernández-Gómez JM; Urology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain., Angulo JC; Urology Department, Hospital Universitario de Getafe, 28905 Getafe, Spain., Medina-Polo J; Urology Department, Research Group in Men's Integral Health, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain., Brenes-Bermúdez FJ; ABS Llefià, 08913 Badalona, Spain., Molero-García JM; San Andrés Primary Care Center, 28021 Madrid, Spain., Fernández-Pro-Ledesma A; Menasalbas Primary Care Center, 45128 Toledo, Spain., Manasanch J; Pierre Fabre Ibérica S.A., 08005 Barcelona, Spain., The Qualiprost Study Group OBO
المصدر: Journal of clinical medicine [J Clin Med] 2020 Sep 09; Vol. 9 (9). Date of Electronic Publication: 2020 Sep 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2012]-
مستخلص: To investigate whether tamsulosin (TAM) and the hexanic extract of Serenoa repens (HESr) are more effective in combination than as monotherapy in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Subset analysis of data from a 6-month, multicenter observational study. Patients received either tamsulosin (0.4 mg/day) or HESr (320 mg/day) alone or in combination. Primary endpoints were change in symptoms and quality of life. Tolerability was also assessed. Seven hundred and nine patients were available for intention to treat (ITT) analysis, 263 treated with tamsulosin, 262 with HESr, and 184 with TAM + HESr. After 6 months, International Prostate Symptom Score (IPSS) scores improved by a mean (standard deviation) of 7.2 (5.0) points in the TAM + HESr group compared to 5.7 (4.3) points with TAM alone and 5.4 (4.6) points with HESr ( p < 0.001). Quality of life showed greatest improvement with combination therapy ( p < 0.02). Adverse effects were reported by 1.9% of patients receiving HESr, 13.3% receiving TAM, and 12.0% receiving TAM + HESr ( p < 0.001). In men with moderate/severe LUTS/BPH, combination treatment with TAM + HESr produced more effective symptom relief and greater improvement in quality of life than with either treatment alone, with acceptable tolerability.
References: Eur Urol Focus. 2016 Dec;2(5):553-561. (PMID: 28723522)
BJU Int. 2012 Sep;110(6 Pt B):E301-7. (PMID: 22520557)
Eur Urol. 2015 Sep;68(3):418-25. (PMID: 25465970)
Prostate Cancer Prostatic Dis. 2009;12(2):152-9. (PMID: 18813219)
BMJ. 2007 Oct 20;335(7624):806-8. (PMID: 17947786)
Prostate. 1999 Sep 1;40(4):232-41. (PMID: 10420151)
J Sex Med. 2014 Jun;11(6):1554-66. (PMID: 24708055)
Urol Int. 2015;94(2):187-93. (PMID: 25614155)
N Engl J Med. 2003 Dec 18;349(25):2387-98. (PMID: 14681504)
N Engl J Med. 1996 Aug 22;335(8):533-9. (PMID: 8684407)
World J Urol. 2012 Jun;30(3):419-26. (PMID: 21892656)
Int J Clin Pract. 2019 Sep;73(9):1-9. (PMID: 30317693)
World J Urol. 2020 Feb 14;:. (PMID: 32060633)
Int Urol Nephrol. 2016 May;48(5):645-56. (PMID: 26810324)
Lancet. 1976 Jun 12;1(7972):1265-8. (PMID: 73694)
Sci Rep. 2017 Nov 9;7(1):15179. (PMID: 29123161)
N Engl J Med. 2006 Feb 9;354(6):557-66. (PMID: 16467543)
BJU Int. 2018 Dec;122(6):1049-1065. (PMID: 29694707)
Prostate. 1998 Oct 1;37(2):77-83. (PMID: 9759701)
Eur Rev Med Pharmacol Sci. 2012 May;16(5):569-74. (PMID: 22774395)
BJU Int. 2006 Apr;97 Suppl 2:3-6; discussion 21-2. (PMID: 16507045)
Prostate Cancer Prostatic Dis. 2004;7(3):195-200. (PMID: 15289814)
BJU Int. 2012 Jun;109(12):1756-61. (PMID: 22551330)
Int J Mol Sci. 2013 Jul 10;14(7):14301-20. (PMID: 23846725)
Can J Urol. 2015 Oct;22 Suppl 1:1-6. (PMID: 26497338)
J Endocrinol Invest. 2015 Jul;38(7):799-805. (PMID: 25778849)
Pharmacology. 2008;82(4):270-5. (PMID: 18849646)
Eur Urol. 2004 Jun;45(6):773-9; disucssion 779-80. (PMID: 15149751)
Eur Urol. 2010 Jan;57(1):123-31. (PMID: 19825505)
Med Care. 1995 Apr;33(4 Suppl):AS145-55. (PMID: 7536866)
J Urol. 1995 Nov;154(5):1770-4. (PMID: 7563343)
Eur Urol. 2019 Jan;75(1):129-168. (PMID: 30293906)
BJU Int. 2009 Apr;103(7):919-26. (PMID: 19239460)
J Pharmacol Sci. 2010;112(2):151-7. (PMID: 20134112)
BJU Int. 2015 Apr;115(4):508-19. (PMID: 24656222)
Eur Urol. 2002 May;41(5):497-506; discussion 506-7. (PMID: 12074791)
Curr Urol Rep. 2014 Dec;15(12):463. (PMID: 25312251)
معلومات مُعتمدة: not applicable Pierre Fabre Ibérica, S.A.
فهرسة مساهمة: Keywords: BII; BPH; combination treatment; hexanic extract of Serenoa repens; moderate-severe LUTS; quality of life; storage symptoms; tamsulosin; tolerability
تواريخ الأحداث: Date Created: 20200912 Latest Revision: 20201027
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7564885
DOI: 10.3390/jcm9092909
PMID: 32917008
قاعدة البيانات: MEDLINE
الوصف
تدمد:2077-0383
DOI:10.3390/jcm9092909